Goldman Sachs Group Inc Blueprint Medicines Corp Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 926,668 shares of BPMC stock, worth $119 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

926,668

Previous 926,668 -0.0%

Holding current value

$119 Million

Previous $82 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$86.69 - $115.63 $10.4 Million - $13.9 Million	-119,867 Reduced 11.45%	926,668 $82 Million
Q4 2024 Feb 11, 2025	BUY	$82.48 - $101.39 $26.8 Million - $32.9 Million	324,903 Added 45.02%	1,046,535 $91.3 Million
Q3 2024 Nov 14, 2024	SELL	$84.1 - $120.5 $1.48 Million - $2.12 Million	-17,606 Reduced 2.38%	721,632 $66.7 Million
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $14.7 Million - $18.8 Million	172,584 Added 30.46%	739,238 $79.7 Million
Q1 2024 May 15, 2024	SELL	$73.17 - $99.79 $834,211 - $1.14 Million	-11,401 Reduced 1.97%	566,654 $53.8 Million
Q4 2023 Feb 13, 2024	BUY	$43.96 - $92.84 $10.3 Million - $21.7 Million	233,337 Added 67.69%	578,055 $53.3 Million
Q3 2023 May 14, 2024	SELL	$46.9 - $66.0 $10.9 Million - $15.4 Million	-233,337 Reduced 40.37%	344,718 $17.3 Million
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $2.09 Million - $2.95 Million	-44,638 Reduced 11.46%	344,718 $17.3 Million
Q2 2023 May 14, 2024	BUY	$42.2 - $66.37 $2.31 Million - $3.63 Million	54,765 Added 16.37%	389,356 $24.6 Million
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $2.31 Million - $3.63 Million	54,765 Added 16.37%	389,356 $24.6 Million
Q1 2023 May 14, 2024	BUY	$37.97 - $50.0 $657,982 - $866,450	17,329 Added 5.46%	334,591 $15.1 Million
Q1 2023 May 11, 2023	BUY	$37.97 - $50.0 $657,982 - $866,450	17,329 Added 5.46%	334,591 $15.1 Million
Q4 2022 May 14, 2024	SELL	$41.06 - $66.48 $217,125 - $351,546	-5,288 Reduced 1.64%	317,262 $13.9 Million
Q4 2022 Feb 13, 2023	SELL	$41.06 - $66.48 $217,125 - $351,546	-5,288 Reduced 1.64%	317,262 $13.9 Million
Q3 2022 May 14, 2024	BUY	$49.93 - $77.7 $3.22 Million - $5 Million	64,406 Added 24.95%	322,550 $21.3 Million
Q3 2022 Nov 10, 2022	BUY	$49.93 - $77.7 $3.22 Million - $5 Million	64,406 Added 24.95%	322,550 $21.3 Million
Q2 2022 May 14, 2024	SELL	$45.23 - $70.15 $14.5 Million - $22.4 Million	-319,911 Reduced 55.34%	258,144 $13 Million
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $2.2 Million - $3.41 Million	-48,632 Reduced 15.85%	258,144 $13 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $5.07 Million - $10.3 Million	-93,695 Reduced 23.4%	306,776 $19.6 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $20 Million - $24.7 Million	-212,594 Reduced 34.68%	400,471 $42.9 Million
Q3 2021 Nov 10, 2021	BUY	$80.98 - $109.47 $49.6 Million - $67.1 Million	613,065 New	613,065 $63 Million

Others Institutions Holding BPMC

# of Institutions

391

Shares Held

68.5M

Call Options Held

1.54M

Put Options Held

1.08M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.64B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Blueprint Medicines Corp Transaction History